Work

Caspofungin Etest Susceptibility Testing of Candida Species: Risk of Misclassification of Susceptible Isolates of C. glabrata and C. krusei when Adopting the Revised CLSI Caspofungin Breakpoints

Year: 2012

Type: article

Abstract: The purpose of this study was to evaluate the performance of caspofungin Etest and the recently revised CLSI breakpoints. A total of 497 blood isolates, of which 496 were wild-type isolates, were included. A total of 65/496 susceptible isolates (13.1%) were misclassified as intermediate (I) or resistant (R). Such misclassifications were most commonly observed for Candida krusei (73.1%) and Candida glabrata (33.1%). The revised breakpoints cannot be safely adopted for these two species.

Source: Antimicrobial Agents and Chemotherapy

DOI: 10.1128/aac.00355-12

Authors: Maiken Cavling Arendrup, Michael A. Pfaller, the Danish Fungaemia Study Group

Institutions: Statens Serum Institut, University of Iowa, JMI Laboratories

Language: English

Topic: Antifungal resistance and susceptibility

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Pfizer, Gilead Sciences, Astellas Pharma, Merck Sharp and Dohme